OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancerhttps://www.nct-dresden.de/en/trials/900-000002327https://www.nct-dresden.de/@@site-logo/logo-nct.svg
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Gynecological tumors / Breast cancer
Breast cancer
Follow-Up Treatment (Metastatic Disease)
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) tothe standard-of-care options of fulvestrant or an aromatase inhibitor in women and menwith breast cancer whose disease has advanced on one endocrine therapy in combinationwith a CDK4/6 inhibitor.
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) tothe standard-of-care options of fulvestrant or an aromatase inhibitor in women and menwith breast cancer whose disease has advanced on one endocrine therapy in combinationwith a CDK4/6 inhibitor.
